Forbes Financial Planning Inc. Takes $241,000 Position in Hims & Hers Health, Inc. $HIMS

Forbes Financial Planning Inc. bought a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the 2nd quarter, according to its most recent filing with the SEC. The fund bought 4,828 shares of the company’s stock, valued at approximately $241,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Smartleaf Asset Management LLC lifted its stake in Hims & Hers Health by 15.7% during the first quarter. Smartleaf Asset Management LLC now owns 1,672 shares of the company’s stock worth $49,000 after purchasing an additional 227 shares during the period. Bessemer Group Inc. lifted its position in shares of Hims & Hers Health by 105.8% during the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after buying an additional 312 shares during the period. True Vision MN LLC boosted its stake in Hims & Hers Health by 3.6% in the 2nd quarter. True Vision MN LLC now owns 9,376 shares of the company’s stock valued at $467,000 after buying an additional 328 shares in the last quarter. Allworth Financial LP boosted its stake in Hims & Hers Health by 20.0% in the 1st quarter. Allworth Financial LP now owns 2,006 shares of the company’s stock valued at $56,000 after buying an additional 334 shares in the last quarter. Finally, Signaturefd LLC grew its position in Hims & Hers Health by 17.7% in the first quarter. Signaturefd LLC now owns 2,586 shares of the company’s stock valued at $76,000 after acquiring an additional 388 shares during the period. Institutional investors own 63.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on HIMS shares. UBS Group set a $32.00 price objective on Hims & Hers Health in a report on Tuesday. Needham & Company LLC reissued a “hold” rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Weiss Ratings restated a “hold (c)” rating on shares of Hims & Hers Health in a research report on Wednesday. Wall Street Zen lowered shares of Hims & Hers Health from a “buy” rating to a “hold” rating in a report on Monday, July 28th. Finally, Truist Financial cut their target price on shares of Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating for the company in a research note on Monday, August 18th. Two investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Reduce” and an average target price of $45.27.

Hims & Hers Health Stock Down 5.0%

NYSE:HIMS opened at $41.53 on Friday. The company has a market cap of $9.39 billion, a price-to-earnings ratio of 76.91, a P/E/G ratio of 8.60 and a beta of 2.20. The company has a debt-to-equity ratio of 1.67, a quick ratio of 4.46 and a current ratio of 1.88. The stock’s fifty day moving average price is $51.30 and its two-hundred day moving average price is $50.72. Hims & Hers Health, Inc. has a 52-week low of $19.15 and a 52-week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, November 3rd. The company reported $0.09 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.09. The company had revenue of $598.98 million during the quarter, compared to the consensus estimate of $578.99 million. Hims & Hers Health had a return on equity of 25.85% and a net margin of 6.05%.The firm’s quarterly revenue was up 49.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.32 earnings per share. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Soleil Boughton sold 2,637 shares of the business’s stock in a transaction that occurred on Monday, October 27th. The shares were sold at an average price of $50.10, for a total transaction of $132,113.70. Following the completion of the sale, the insider directly owned 158,493 shares of the company’s stock, valued at $7,940,499.30. The trade was a 1.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Michael Chi sold 900 shares of the firm’s stock in a transaction that occurred on Friday, October 10th. The shares were sold at an average price of $58.25, for a total transaction of $52,425.00. Following the completion of the transaction, the insider directly owned 291,439 shares in the company, valued at approximately $16,976,321.75. The trade was a 0.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 712,271 shares of company stock worth $37,631,985 in the last 90 days. Corporate insiders own 13.71% of the company’s stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.